Abiologics

Executive Summary

Abiologics is pioneering a new class of programmable biologics called Synteins™, leveraging artificial intelligence and chemistry to create supranatural therapeutics that transcend the limitations of natural biology. Founded in 2016 and headquartered in San Diego, the company aims to address a broad range of diseases by designing novel protein-like molecules that are more stable, penetrant, and specific than traditional biologics. While still in the early stages, Abiologics' platform has the potential to unlock previously undruggable targets and improve patient outcomes. The company is privately held and has not disclosed total funding or valuation, but its innovative approach positions it as an emerging player in the AI-driven biologics space. Key risks include the inherent challenges of computational design, manufacturing scalability, and clinical validation. However, the convergence of AI and synthetic chemistry offers a compelling differentiation from conventional biologics, warranting close monitoring of future developments.

Upcoming Catalysts (preview)

• H1 2026Series A Funding Announcement70% success
• H2 2026Preclinical Proof-of-Concept Data for Lead Syntein Program60% success
• 2026Strategic Partnership with Large Pharma50% success